 | Up a level |
Kurch, L; Hasenclever, D; Kluge, R; Georgi, T; Tchavdarova, L; Golombeck, M; Sabri, O; Eggert, A; Brenner, W; Sykora, K W; Bengel, F M; Rossig, C; Körholz, D; Schäfers, M; Feuchtinger, T; Bartenstein, P; Ammann, Roland; Krause, T; Urban, C; Aigner, R; ... (2019). Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. Pediatric blood & cancer, 66(3), e27539. Wiley-Liss 10.1002/pbc.27539
Borte, M; Horneff, G; Kempf, Christoph; Kaise, R; Korinthenberg, R; Körholz, D; Mauz-Körholz, C; Nadal, D; Niggemann, B; Roos, R; Späth, Peter; Wahn, V; Wehmeier, A; Zepp, F; Zielen, S (2007). Herstellung von intravenös verabreichbaren Immunglobulinen und Pathogensicherheit. In: Wahn, Volker (ed.) Klinischer Einsatz von Immunglobulinen (pp. 28-47). Bremen et al.: UNI-MED
